Psychedelics were once, not so long ago, held up by select vocal advocates as a New Panacea for difficult-to-treat (or treatment-resistant) depression, as psychological ‘antibiotics’ that would revolutionise psychiatry. Then came the naysayers, those with vehement reservations about the science of psychoactives. Rivers of ink were spilled in the literature over methodology, veracity, validity.